


Freelite[®] & Hevylite[®] Assays


The optimal combination for the management of monoclonal gammopathy patients



Freelite assays

The **Freelite** assays are two sensitive and specific polyclonal immunodiagnostic tests to measure κ and λ FLCs in serum.

The κ/λ FLC ratio is a sensitive marker of light chain clonality.




Freelite assays are the only FLC tests recommended by both national and international guidelines.

Improve your accuracy in detecting monoclonal gammopathies

Hevylite assays

Hevylite assays identify and quantify individual heavy + light chain (HLC) isotypes, i.e. IgG κ , IgG λ , IgA κ , IgA λ , IgM κ and IgM λ .

These molecules are measured in pairs, e.g. IgG κ /IgG λ , to produce ratios in the same manner as the κ/λ sFLC ratio.



The Hevylite assay works by targeting epitopes between the heavy chain and light chain constant regions.

“ The HLC assays allow new ways to examine plasma cell biology and disease. We are able to identify abnormalities that were previously hidden from our view...”¹

Freelite and Hevylite assays in Monoclonal Gammopathy testing

Diagnosis

Multiple Myeloma

- **Freelite** assays determine a “myeloma defining event”*
- **Freelite** assays and SPE are an efficient aid in screening and diagnosis
- **Freelite** assays are recommended to rule out cast nephropathy

MGUS

- **Freelite** and **Hevylite** assays for risk stratification and prognosis

Monitoring

Clonal change

- **Freelite** and **Hevylite** assays measure two independent biomarkers
- **Freelite** and **Hevylite** assays to follow clonal change
- **Freelite** assays to detect light chain escape

Difficult to measure monoclonal proteins

- **Freelite** and **Hevylite** assays to monitor oligosecretory MM
- **Freelite** assays to monitor LCMM, NSMM and AL amyloidosis
- **Hevylite** assays to monitor when electrophoresis is inaccurate or insensitive


Residual Disease


Depth of response

- **Freelite** and **Hevylite** assays capture more residual disease
- **Freelite** and **Hevylite** assays as gateway tests to MRD analysis
- **Freelite** assays to define stringent complete response

SPE = Serum Protein Electrophoresis MGUS = Monoclonal Gammopathy of Undetermined Significance MM = Multiple Myeloma LCMM = Light Chain Multiple Myeloma
NSMM = Nonsecretory Multiple Myeloma MRD = Minimal Residual Disease * Involved/uninvolved sFLC ratio ≥ 100 and involved Freelite $\geq 100\text{mg/L}$

Freelite and Hevylite in the management of Monoclonal Gammopathies





Diagnosis

IMWG Guidelines for Diagnosis of Multiple Myeloma

IMWG Criteria for MM diagnosis²

Clonal bone marrow plasma cells $\geq 10\%$ or biopsy-proven bony or extramedullary plasmacytoma and one or more myeloma defining events:

One or more biomarkers of malignancy (**SLiM**)

- Clonal bone marrow plasma cells $\geq 60\%$ (**S**ixty %)
- **I**nvolvement/uninvolved serum **F**ree **L**ight **C**hain ratio $\geq 100^*$
- >1 focal lesion on **M**RI studies

* By Freelite (iFLC must be $\geq 100\text{mg/L}$)

OR

Related end organ damage (**CRAB**)

- Hyper**C**alcaemia
- **R**enal insufficiency
- **A**naemia
- **B**one lesions

Freelite forms part of the IMWG diagnostic criteria for MM


Use Freelite and Hevylite together

The IMWG guidelines recommend **Freelite** assays for the diagnosis of monoclonal gammopathies.³ The assay quantitatively measures free light chains providing improved accuracy compared to traditional methods.

Freelite assays should be used with SPE in the initial testing of patients to detect monoclonal gammopathies, allowing urine testing to be used more selectively.^{3,4}

Hevylite assay results provide a baseline value that is useful in monitoring and prognosis. It can also help to clarify problematic SPE results.

At Diagnosis



Diagnose more monoclonal gammopathies with Freelite and Hevylite assays

IMWG = International Myeloma Working Group SPE = Serum Protein Electrophoresis sIFE = serum Immunofixation Electrophoresis
uIFE = urine Immunofixation Electrophoresis

Optimising your Diagnostic Approach for Monoclonal Gammopathy Testing

A combination of **Freelite** assays and SPE is a clinically sensitive strategy for diagnosis of monoclonal gammopathies⁴.

Protocols	% of Paraproteins detected			
	*Myeloma ⁴	AL amyloidosis ⁴	LCMM ^{5,6,7}	NSMM ⁸
SPE alone	88	66	40 - 57	0
Serum IFE	94	74	n.d.	0
SPE, serum IFE, urine IFE	100	94	n.d.	0
SPE/CZE and Freelite assays	100	96	100	68
SPE/CZE, Freelite assays and serum IFE	100	97	100	68

* Myeloma is inclusive of 467 patients with MM (451), NSMM (4), Plasma cell leukaemia (4), Osteosclerotic MM (1), and Indolent Myeloma (7).

NICE Guidelines recommend SPE and sFLC assessment to screen for monoclonal protein in patients with suspected myeloma

“urine testing was only done in a fraction of the people being tested. This could have resulted in potential missed diagnoses if the sFLC test was not performed as an alternative”⁹

Detect more monoclonal gammopathies with Freelite assays as recommended by IMWG

MGUS risk stratification improves patient management

Risk stratification is recommended for all MGUS patients to optimise counselling and follow-up, based on three independent risk factors:¹⁰

1. Abnormal κ/λ sFLC ratio
2. Serum monoclonal protein ≥ 15 g/L
3. IgA or IgM type


Extended risk stratification:¹¹

4. **Hevylite** assays (HLC) pair suppression*

Hevylite assays pair suppression is a new, independent biomarker for identifying MGUS patients at high risk of malignant progression.

*When the concentration of the uninvolved HLC is below the normal reference interval, provided the HLC ratio is abnormal.

MGUS risk stratification using 4 risk factors



25% of patients with 4 risk factors developed MM or a related condition within two years.¹¹

Freelite & Hevylite assays allow optimal risk stratification of MGUS patients

sFLC = serum Free Light Chain HLC = Heavy + light chain isotypes MGUS = Monoclonal Gammopathy of Undetermined Significance MM = Multiple Myeloma


Detect Myeloma Kidney early to increase the chance of renal recovery

Up to 45% of newly diagnosed myeloma patients will have renal insufficiency, 20% will have severe renal impairment and 3.5% will have renal failure requiring dialysis.¹²

90% of renal failure in multiple myeloma is due to cast nephropathy (myeloma kidney).¹³

Irreversible kidney damage can be prevented by early detection of nephrotoxic monoclonal FLCs using **Freelite** assays, followed by myeloma treatment.

The International Kidney and Monoclonal Gammopathy Research Group recommend sFLC analysis for the investigation of new, unexplained AKI.¹⁴




* Positive = k/l ratio outside 0.37 - 3.1

Rapid diagnosis & treatment is essential for improving outcomes in cast nephropathy

Monitoring

Use Freelite and Hevylite assays together for optimal management of Multiple Myeloma patients



Use Freelite and Hevylite assays together:


- To quantitatively monitor patients with Multiple Myeloma
- To identify clonal change

SPE = Serum Protein Electrophoresis CZE = Capillary Zone Electrophoresis dFLC = involved Free Light Chain minus the uninvolved Free Light Chain


Serum Freelite assay results provide more accurate information than urine BJP

Shown here are two Light Chain Multiple Myeloma patients being monitored by serum **Freelite** assays (shown in red) and UPE (uBJP - shown in blue).


In both cases, measurement of uBJP overestimates the response to treatment but **Freelite** assays correctly indicate residual disease.¹⁵



dFLC indicates no response to therapy where UPE and uIFE become negative at cycle 2.




dFLC indicates a VGPR (very good partial response) at the end of cycle 2 and presence of residual disease whereas UPE and uIFE became negative and yielded no information on residual disease.



SIFE confirmed the presence of residual disease.

SIFE Cycle 2







SIFE confirmed the presence of residual disease.

Greater biological relevance of sFLC analysis over urine for LCMM

The increased sensitivity of sFLC analysis when monitoring Light Chain Multiple Myeloma patients translates into valuable prognostic information.

Post therapy, patients with an abnormal sFLC ratio had a worse outcome.

uIFE provided no prognostic information.¹⁶







*"...serum FLC analysis is the method of choice for response evaluation in LCMM patients..."*¹⁶

Hevylite assays overcome the difficult measurement of IgA monoclonal proteins

IgA monoclonal proteins are often difficult to quantify, and therefore difficult to monitor, by SPE.

This can be due to small bands, broadly migrating bands, or co-migration with other serum proteins.

Accurate numerical values by **Hevylite** assays make it easier to monitor IgA Multiple Myeloma patients.

SPE for patients 1-3	IFE for Patient 1	IFE for Patient 2	IFE for Patient 3
			
	IFE is used here to confirm why SPE is not quantifiable in these 3 patients:		
	Patient 1	Patient 2	Patient 3
	The IgA κ band is too small to quantify by SPE	The broadly migrating IgA κ is hard to separate from the polyclonal background on SPE	IgA λ co-migrates with other serum proteins on SPE
Hevylite ratio	37.17 (Abnormal)	44.39 (Abnormal)	0.17 (Abnormal)
dHLC	3.58	16.62	4.44

Arrows indicate monoclonal immunoglobulin on IFE

All 3 patients had abnormal **Hevylite** assay ratios, indicating monoclonality. When the **Hevylite** assays ratio is abnormal, these patients can also be monitored using dHLC.

*“The **Hevylite** assay...can overcome limitations associated with monitoring beta-migrating monoclonal IgA by electrophoresis”¹⁷*

Use Hevylite assays when electrophoresis is inaccurate


Accurately monitor low levels of monoclonal protein <10g/L

Oligosecretory disease - Monitor with Hevylite and Freelite

Freelite assays are recommended by IMWG guidelines for monitoring Oligosecretory Multiple Myeloma due to their high sensitivity compared to traditional techniques.^{3, 18}

The IMWG consensus criteria for response and MRD assessment in multiple myeloma acknowledge the value of using **Hevylite** assays in such cases.

*“The **Hevylite** assay is useful in patients with oligo-secretory disease...”¹⁷*




This IgAκ myeloma patient presented with very low levels of monoclonal protein. At Complete Response, SPE and total IgA are normal until disease progression (PD) but the patient’s monoclonal protein can be monitored throughout using **Hevylite** assays. The **Hevylite** assays ratio does not normalise, indicating residual disease

Use Hevylite assays when electrophoresis is insensitive

IMWG = International Myeloma Working Group SPE = Serum Protein Electrophoresis Ig = Immunoglobulin CR = Complete Response PD = Progressive Disease
dHLC = involved Heavy + Light Chain isotype - uninvolved Heavy + Light Chain isotype UNL = Upper normal limit MRD = Minimal Residual Disease

Clonal Diversity at relapse

Serum FLCs and intact immunoglobulins are independent tumour markers.



Monoclonal protein type detected at relapse and progression can be different to those seen at diagnosis.¹⁹

1. Free light chain only patients showed no change
2. 62% of patients with both intact immunoglobulins and FLCs changed their monoclonal protein type
3. 17% of patients with only intact immunoglobulins changed their monoclonal protein type

Overall, **44%** of patients changed their monoclonal protein type at relapse.

Used together, Freelite and Hevylite assays can identify clonal change at relapse


Detect Light Chain Escape to improve patient outcome

For some IIMM patients, relapse is accompanied by a marked rise in monoclonal sFLC with no associated increase in intact immunoglobulin concentrations.

This phenomenon is known as light chain escape or Bence Jones escape.

Patients who relapse with any light chain involvement have poorer prognosis than those relapsing with intact immunoglobulins only.²⁰

10% of IIMM patients (20% of IgA IIMM) relapse with FLC only.



Courtesy of Christie Hospital, Manchester, UK.

This Intact Immunoglobulin MM patient was monitored following bortezomib treatment (▼). Both IgAλ and λ serum FLC levels decrease in response to treatment and remain stable for many months.

Subsequent relapse with LCE was only detected by **Freelite** assays.

Monitor with Freelite assays to ensure Light Chain Escape is not missed²⁰


MM = Multiple Myeloma LCE = Light Chain Escape FLC = Free Light Chain sFLC = serum Free Light Chain IIMM = Intact Immunoglobulin Multiple Myeloma

Use Freelite and Hevylite assays together to capture clonal change

Freelite and **Hevylite** assays measure two independent biomarkers in Multiple Myeloma.

- **Freelite** assays measure kappa(κ) and lambda(λ) free light chains (mg/L)
- **Hevylite** assays measure intact monoclonal immunoglobulins (g/L)

When used together, **Freelite** assays and **Hevylite** assays provide more accurate information on multiple myeloma disease course, as highlighted by this case example of IgA kappa Multiple Myeloma.



The patient presented with abnormal **Hevylite** and **Freelite** assay ratios. Following treatment both the **Hevylite** assays ratio and κFLC concentrations normalise.


By day 900 the patient relapsed with an increase in IgA **Hevylite** assays ratio but little change in the κFLC levels.

After further treatment the **Hevylite** assays ratio did not normalise. Further relapse was seen at around 2000 days with both an increase in the **Hevylite** ratio and κFLC concentration.

Freelite and **Hevylite** assays are both quantitative and easy to use, combining accurate results with high sensitivity, enabling rapid identification of clonal change at relapse.

Residual Disease

Use Freelite and Hevylite assays together as gateway tests to MRD assessment



* Normal Freelite ratio to help define Stringent Complete Response

Negative
IMWG MRD
criteria

+

Normal
Hevylite
assays ratio


=

“Composite endpoint reflecting the eradication of tumour cells from all compartments and recovery of the normal plasma-cell population to the currently available level of detection”¹⁷

To provide additional sensitivity use Freelite and Hevylite assays together

NGF = Next Generation Flow Cytometry NGS = Next Generation Sequencing MRD = Minimal Residual Disease IMWG = International Myeloma Working Group

Freelite assays are essential for assessing sCR in all myeloma patients



Complete Response

- Negative serum/urine IFE
- BM plasma cells <5%

Stringent Complete Response


- Negative serum/urine IFE
- Absence of clonal cells in BM
- **Normal sFLC ratio**

Patients who managed to reach sCR after ASCT transplantation had significantly improved overall survival. Those who could sustain a sCR for at least 6 months had the best overall survival.²¹

Patients who achieved a sCR had significantly longer survival than those who achieved a CR

sCR = stringent Complete Response CR = Complete Response IFE = Immunofixation Electrophoresis nCR = Near Complete Response
sFLC = Serum Free Light Chains BM = Bone Marrow ASCT = Autologous Stem Cell Transplant

Use Hevylite assays to capture more residual disease



The increased sensitivity of **Hevylite** assays can indicate the presence of residual disease in patients classified as being in Complete Response by other methods (D).²²

The abnormal **Hevylite** assays ratio of this patient in B-D is produced by immunosuppression of the uninvolved immunoglobulin (IgAλ) rather than an increase in the involved IgAκ, highlighting the unique information provided by **Hevylite** assays.


Red = abnormal Hevylite/Freelite assays result

“It is probable that the [Hevylite assay] test not only allows for the detection of persistent secretory clones of plasma cells, but it is also an indicator of the normalisation of the immune system.”¹⁷

More information for better patient care decisions

IF = Immunofixation Electrophoresis SPE = Serum Protein Electrophoresis HLC = Heavy + Light Chain Isotypes FLC = Free Light Chain

International Myeloma Working Group (IMWG) Consensus Criteria for Response and MRD Assessment in Multiple Myeloma¹⁷




"The **Hevylite**® assay is useful in patients with **oligo-secretory** disease and can overcome limitations associated with **monitoring β -migrating monoclonal IgA** by electrophoresis"

"In most cases, responses assigned by the **Hevylite** assay have shown to be equivalent to those assigned by conventional methods (SPE, IFE, nephelometry). In some cases, however, **heavy/light chain ratios provided additional sensitivity**"

"It is probable that the [**Hevylite**] test not only allows for detection of persistent secretory clones of plasma cells, but it is also an **indicator of the normalisation** of the immune system"

Of course, a normal **Freelite**® assays ratio is required to define **sCR**



Freelite and Hevylite assays measure two independent biomarkers in Myeloma

Key Terminology

Freelite assays

Term	Definition	Description	Example in κ light chain MM
FLC	Free Light Chain		
iFLC	Involved FLC	FLC type produced by the tumour	κ
uFLC	Uninvolved FLC	FLC type that is the alternate light chain type to the iFLC	λ
κ/λ sFLC ratio	κ/λ	Ratio of the concentration of κ to λ sFLCs (indicates clonality)	κ/λ
dFLC	iFLC – uFLC	Difference in concentration between iFLC and uFLC	$\kappa - \lambda$
iFLC/uFLC ratio		Ratio of the concentration of iFLC to uFLC (can be κ/λ or λ/κ)	κ/λ

Hevylite assays

Term	Definition	Description	Example in an IgA κ MM patient
HLC	Heavy + light chain isotypes	Measures heavy/light chain combination, not separately	
iHLC	Involved HLC	HLC isotype produced by the tumour	IgA κ
uHLC	Uninvolved HLC	The same heavy chain isotype but alternate light chain type to the iHLC	IgA λ
HLC ratio	e.g. IgA κ /IgA λ	For a particular immunoglobulin isotype, a ratio of the concentration of Hevylite κ to λ (indicates clonality)	IgA κ /IgA λ
dHLC	iHLC – uHLC	For a particular immunoglobulin isotype, the difference in concentration between the iHLC and uHLC	IgA κ -IgA λ
Hevylite pair suppression	When the concentration of the uHLC is below the normal reference interval	The HLC ratio must be abnormal	Suppression of IgA λ

Reference ranges

Freelite assays

Normal adult serum	95 percentile range
κ FLC	3.30 - 19.40 (mg/L)
λ FLC	5.71 - 26.30 (mg/L)
κ / λ FLC ratio	100 percentile range
	0.26 - 1.65

An abnormal κ/λ FLC ratio is a highly sensitive indicator of monoclonal κ or λ FLC in serum. A study showed that patients with renal impairment had increased levels of FLC in serum and proposed an extended **Freelite** ratio reference range κ/λ FLC ratio: 0.37-3.1 for these patients.²³

Renal reference range	100 percentile range
κ / λ FLC ratio	0.37 - 3.1

The renal reference range improves specificity whilst maintaining diagnostic sensitivity in patients with renal impairment.

Values outside of this range are consistent with the presence of monoclonal sFLC's in these patients.

Hevylite assays

Normal adult serum	95 percentile range for Optilite®
IgG Kappa	4.03 - 9.78 (g/L)
IgG Lambda	1.97 - 5.71 (g/L)
IgGκ/IgGλ Ratio	0.98 - 2.75
IgA Kappa	0.588 - 2.984 (g/L)
IgA Lambda	0.432 - 2.035 (g/L)
IgAκ/IgAλ Ratio	0.911 - 2.416
IgM Kappa	0.19 - 1.63 (g/L)
IgM Lambda	0.12 - 1.01 (g/L)
IgMκ/IgMλ Ratio	1.18 - 2.74

Key Guidelines

Year	Guidelines	Author & Publication Information
2016	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.	Kumar, <i>et al. Lancet Oncology</i> 2016; 17:e328-346
2016	National Institute for Health and Care Excellence (NICE). Myeloma: diagnosis and management.	NICE publication (UK)
2016	National Comprehensive Cancer Network (NCCN). Clinical practice Guidelines in Oncology - Multiple Myeloma	Anderson KC, <i>et al</i> ; NCCN publication
2014	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.	Rajkumar SV, <i>et al. Lancet Oncology</i> 2014; 15:e538-e548
2014	International Myeloma Working Group recommendations for global myeloma care.	Ludwig H, <i>et al. Leukemia</i> 2014; 28:981-992
2012	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes.	Palladini, <i>et al. J Clin Onc</i> 2012; 30:4541-4549
2011	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.	Rajkumar SV, <i>et al. Blood</i> 2011; 117:4691-4695
2010	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.	Kyle RA, <i>et al. Leukemia</i> 2010; 24:1121-1127
2009	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.	Dispenzieri A, <i>et al. Leukemia</i> 2009; 23:215-224
2006	International uniform response criteria for multiple myeloma.	Durie BGM, <i>et al. Leukemia</i> 2006; 20:1467-1473

References

1. Katzmann, J.A. and Rajkumar, S.V., A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains. *Leukemia*, 2013. 27(1): p. 1-2.
2. Rajkumar, S.V., *et al.*, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology*, 2014. 15: p. e538-e548.
3. Dispenzieri, A., *et al.*, International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*, 2009. 23(2): p. 215-224.
4. Katzmann, J.A., *et al.*, Screening panels for detection of monoclonal gammopathies. *Clin Chem*, 2009. 55(8): p. 1517-1522.
5. Bradwell, A.R., *et al.*, Serum test for assessment of patients with Bence Jones myeloma. *Lancet*, 2003. 361(9356): p. 489-491.
6. Wolff, F., C. Thiry, and D. Willems, Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. *Clin Biochem*, 2007. 40(5-6): p. 351-354.
7. Abraham, R.S., *et al.*, Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. *Clin Chem*, 2002. 48(4): p. 655-657.
8. Drayson, M., *et al.*, Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. *Blood*, 2001. 97(9): p. 2900-2902.
9. Myeloma: diagnosis and management. NICE Guidelines, 2016.
10. Kyle, R.A., *et al.*, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*, 2010. 24(6): p. 1121-1127.
11. Katzmann, J.A., *et al.*, Suppression of uninvolved immunoglobulins defined by heavy/light-chain pair suppression is a risk factor for progression of MGUS. *Leukemia*, 2013. 27(1): p. 208-212.
12. Dimopoulos, M.A., *et al.*, Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. *Ann Oncol*, 2014. 25(1): p. 195-200.
13. Cockwell, P. and C.A. Hutchison, Management options for cast nephropathy in multiple myeloma. *Curr Opin Nephrol Hypertens*, 2010. 19(6): p. 550-555.
14. Hutchison, C.A., *et al.*, The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. *Nat Rev Nephrol*, 2011. 8(1): p. 43-51.
15. Dejoie, T., *et al.*, Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. *Haematologica*, 2016. 101(3): p. 356-62.
16. Dejoie, T., *et al.*, Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines. *Blood*, 2016. 7: p. 726-778
17. Kumar, S., *et al.*, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*, 2016. 17(8): p. e328-46.
18. Durie, B.G., *et al.*, International uniform response criteria for multiple myeloma. *Leukemia*, 2006. 20(9): p. 1467-1473.
19. Zamarin, D., *et al.*, Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. *Bone Marrow Transplant*, 2013. 48(3): p. 419-424.
20. Brioli, A., *et al.*, Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma. *Blood*, 2014. 123(22): p. 3414-3419.
21. Kapoor, P., *et al.*, Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. *J Clin Oncol*, 2013. 31(36): p. 4529-4535.
22. Ludwig, H., *et al.*, Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. *Leukemia*, 2013. 27(1): p. 213-219.
23. Hutchison, C.A., *et al.*, Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. *BMC Nephrol*, 2008. 9(11): p. 1-8.

Learn More

Quality Assurance



Our manufacturing site has quality systems approved to ISO13485 certification. This, together with strict adherence to rigorous internal quality control procedures, ensure customers can be confident in the quality of Binding Site products.



Assays for *in vitro* diagnostic use have been FDA cleared for the USA and CE marked for Europe. Performance of our assays is regularly monitored by participation in a number of independent national and international quality assurance schemes.

Contact us:

www.bindingsite.com

Freelite, Hevylite and Optilite are registered trademarks of
The Binding Site Group Ltd (Birmingham, UK) in certain countries.

Literature not for use in USA.

Follow us on



Go to www.bindingsite.com to contact us in over 80 countries.



October 2021
MKG1051